Explore the words cloud of the TRAIN-HEART project. It provides you a very rough idea of what is the project "TRAIN-HEART" about.
The following table provides information about the project.
|Coordinator Country||Netherlands [NL]|
|Total cost||3˙940˙388 €|
|EC max contribution||3˙940˙388 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2019-06-01 to 2023-05-31|
Take a look of project's partnership.
|1||UNIVERSITEIT MAASTRICHT||NL (MAASTRICHT)||coordinator||531˙239.00|
|2||KING'S COLLEGE LONDON||UK (LONDON)||participant||606˙345.00|
|3||HUMANITAS MIRASOLE SPA||IT (ROZZANO (MI))||participant||522˙999.00|
|4||TECHNISCHE UNIVERSITAET MUENCHEN||DE (MUENCHEN)||participant||505˙576.00|
|5||UNIVERSIDADE DO PORTO||PT (PORTO)||participant||475˙440.00|
|6||UNIVERSITE LYON 1 CLAUDE BERNARD||FR (VILLEURBANNE CEDEX)||participant||274˙802.00|
|7||MIRABILIS THERAPEUTICS BV||NL (MAASTRICHT)||participant||265˙619.00|
|8||MEDIZINISCHE HOCHSCHULE HANNOVER||DE (HANNOVER)||participant||252˙788.00|
|9||MILTENYI BIOTEC GMBH||DE (BERGISH GLADBACH)||participant||252˙788.00|
|10||UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF||DE (HAMBURG)||participant||252˙788.00|
|11||ACCELERO BIOANALYTICS GMBH||DE (BERLIN)||partner||0.00|
|12||DESCIN BV||NL (Vinkeveen)||partner||0.00|
|13||EHT TECHNOLOGIES GMBH||DE (HAMBURG)||partner||0.00|
|15||KANEKA EUROGENTEC||BE (SERAING)||partner||0.00|
|16||SOCIETE EUROPEENNE DE CARDIOLOGIE||FR (BIOT SOPHIA ANTIPOLIS)||partner||0.00|
TRAIN-HEART brings together leading academic teams and (biotech) companies to train the next-generation of innovation-minded researchers who can expand the scientific horizons and accelerate future development of RNA-based therapeutics for the treatment of ischemic heart failure. Under chronic cardiac stress, non-coding RNAs, in particular microRNAs and long non-coding RNAs, act as critical regulators of cardiac tissue remodelling. Innovative therapies targeting these RNA molecules hold great promise in treating the underlying causes of ischemic heart failure. With the exception of heart transplantation, there is no curative therapy available for this detrimental disease. Given the challenges related to delivery, specificity and tolerability of RNA therapeutics, developments in chemically modified oligonucleotides and drug delivery strategies are growing substantially. TRAIN-HEART’s proposition is to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems. TRAIN-HEART provides such training in a European network of top-level academic teams and (biotech) companies active in the fields of cardiovascular biology, functional genomics and drug development. All individual research projects demonstrate multidisciplinary content and supervision arrangements, momentous intersectoral exchanges and international synergies. These PhD programmes are complemented with the right combination of specialised research- and transferable skills trainings to encourage excellent science, innovation and long-term employability. The TRAIN-HEART fellows are envisioned to become entrepreneurial researchers who are keen to bring cutting-edge scientific concepts in RNA therapeutics to the clinic.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRAIN-HEART" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRAIN-HEART" are provided by the European Opendata Portal: CORDIS opendata.